OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.


"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.


OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.


Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology



El hospital CIMA Sanitas es el primer hospital privado de Cataluña en utilizar un novedoso test para el diagnóstico no invasivo del hígado graso

La enfermedad de hígado graso no alcohólico (NAFLD, en inglés) comprende desde la esteatosis (hígado graso) hasta la más grave esteatohepatitis no alcohólica (en inglés, NASH), que puede evolucionar a cirrosis y cáncer hepático. El NAFLD está relacionado con la obesidad y diabetes, afecta al 20-30% de la población y se estima que pasará a ser la principal causa de trasplante hepático en pocos años.


OWL is a trading name of
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 03/08/2018

With the collaboration of: